Dr. Machiels on Pembrolizumab in Head and Neck Cancer

Jean-Pascal Machiels, MD
Published: Thursday, Jun 22, 2017



Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses pembrolizumab (Keytruda) in patients with head and neck cancer.

A hope with pembrolizumab is to administer it to patients earlier in their treatment, explains Machiels. Additionally, looking at combinations with checkpoint inhibitors can have a potential impact on treatment.
 


Jean-Pascal Machiels, MD, head of the Department of Medical Oncology, Cliniques Universitaires Sain-Luc, discusses pembrolizumab (Keytruda) in patients with head and neck cancer.

A hope with pembrolizumab is to administer it to patients earlier in their treatment, explains Machiels. Additionally, looking at combinations with checkpoint inhibitors can have a potential impact on treatment.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Evolving Applications of Immuno-Oncology Strategies: New Approaches, New Combinations, and New Ways to Care for Lung, Head and Neck, and Bladder CancersAug 31, 20182.0
Publication Bottom Border
Border Publication
x